Amid global market ups and downs, TipRanks provides useful tools to help investors make decisions. One of its most powerful tools is the Smart Score, which rates stocks from 1 to 10 and shows their potential to outperform the market. Using this tool, we’ve identified three standout stocks: Satellogic (SATL), Xcel Energy (XEL), and Capricor Therapeutics (CAPR). Each of these has earned a top Smart Score and a Strong Buy rating from Wall Street analysts.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The TipRanks Smart Score rates the stocks on a scale from 1 to 10, with 10 being the highest. The score is based on eight key market factors, including Wall Street analyst ratings, insider transactions, financial blogger opinions, and more. Additionally, the Top Smart Score Stocks list offers a comprehensive selection of stocks rated a perfect 10, along with advanced filtering options.
Let’s dive into the details.
Satellogic (SATL)
Satellogic builds and operates Earth-observation satellites to provide high-resolution geospatial data for industries worldwide. Year-to-date, SATL stock has gained over 200%.
Looking ahead, Wall Street analysts remain bullish, with three covering analysts giving it a Buy rating. Meanwhile, Satellogic’s average stock price target of $6.75 suggests a potential upside of 14% from current levels.
Xcel Energy (XEL)
Xcel Energy is a utility company that generates, distributes, and sells electricity and natural gas across multiple states. Year-to-date, XEL stock has gained 6%.
Wall Street analysts remain bullish on its upside potential, with 10 out of 11 analysts covering XEL stock, rating it as a Buy. According to TipRanks, the stock has a price target of $91.0, implying a 16.53% upside from current levels.
Capricor Therapeutics (CAPR)
Capricor Therapeutics is a clinical-stage biotechnology company developing cell and exosome therapies for cardiovascular and rare diseases. So far in 2026, CAPR stock has gained 0.14%.
CAPR stock carries a Strong Buy rating, with eight Buys assigned in the past three months. The average price target of Capricor Therapeutics is $55.13, which implies a potential upside of 90.7%.
